A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
Recruiting · NCT07612189 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-09-25 | NCT07612189 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| NEOK Bio, Inc. | 2 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| NEXT Oncology | San Antonio | United States | 1 |
| NEXT Oncology | Houston | United States | 5 |
| NEXT Oncology | Fairfax | United States | 31 |
| NEXT Oncology | Austin | United States | 8 |
| NEXT Oncology | Dallas | United States | 1 |
| Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona DDU | Orlando | United States | 1 |
| Sarah Cannon Research Institute at Mary Crowley | Dallas | United States | 7 |
| Sarah Cannon Research Institute Oncology Partners | Nashville | United States | 12 |